Streetwise Reports' Article Archives — Current Month (13)

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook (12/10/2019)

Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020.


ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck (12/09/2019)

ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20.


Antibiotic Alternative for Livestock Feed Approved for Malaysia (12/07/2019)

Now, the company has the green light to sell this product in eight countries.


Imagin Medical Poised for Breakout with Bladder Cancer Detection Device (12/06/2019)

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked.


Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data (12/06/2019)

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif.


Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data (12/05/2019)

Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20.


Immuno-Oncology Firm Expands Agreement with AbbVie (12/04/2019)

The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report.


Company Vies for New Brunswick Cannabis Contract (12/04/2019)

The opportunity is one of the largest in retail cannabis in Canada.


Cannabis Producer Signs Supply Contract with Province of Alberta (12/04/2019)

To start, the company will introduce its premium brand of dried flower there.


INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously (12/04/2019)

Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system.


Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results (12/04/2019)

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia.


Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial (12/03/2019)

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study.


Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug (12/02/2019)

Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.


More Archives

2019Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes